These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 34262897)

  • 1. Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering.
    Gähwiler EKN; Motta SE; Martin M; Nugraha B; Hoerstrup SP; Emmert MY
    Front Cell Dev Biol; 2021; 9():639699. PubMed ID: 34262897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. May I Cut in? Gene Editing Approaches in Human Induced Pluripotent Stem Cells.
    Brookhouser N; Raman S; Potts C; Brafman DA
    Cells; 2017 Feb; 6(1):. PubMed ID: 28178187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of CRISPR/Cas9 Technology on Cardiac Research: From Disease Modelling to Therapeutic Approaches.
    Motta BM; Pramstaller PP; Hicks AA; Rossini A
    Stem Cells Int; 2017; 2017():8960236. PubMed ID: 29434642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy.
    Al Abbar A; Ngai SC; Nograles N; Alhaji SY; Abdullah S
    Biores Open Access; 2020; 9(1):121-136. PubMed ID: 32368414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells.
    Vassena R; Heindryckx B; Peco R; Pennings G; Raya A; Sermon K; Veiga A
    Hum Reprod Update; 2016 Jun; 22(4):411-9. PubMed ID: 26932460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted mutagenesis in human iPSCs using CRISPR genome-editing tools.
    Long Y; Cech TR
    Methods; 2021 Jul; 191():44-58. PubMed ID: 33444739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases.
    Cai B; Sun S; Li Z; Zhang X; Ke Y; Yang J; Li X
    Hum Genet; 2018 Sep; 137(9):679-688. PubMed ID: 30203114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Broad Overview and Review of CRISPR-Cas Technology and Stem Cells.
    Waddington SN; Privolizzi R; Karda R; O'Neill HC
    Curr Stem Cell Rep; 2016; 2(1):9-20. PubMed ID: 27398291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Induced Pluripotent Stem Cell NEUROG2 Dual Knockin Reporter Lines Generated by the CRISPR/Cas9 System.
    Li S; Xue H; Wu J; Rao MS; Kim DH; Deng W; Liu Y
    Stem Cells Dev; 2015 Dec; 24(24):2925-42. PubMed ID: 26414932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR technologies for stem cell engineering and regenerative medicine.
    Hsu MN; Chang YH; Truong VA; Lai PL; Nguyen TKN; Hu YC
    Biotechnol Adv; 2019 Dec; 37(8):107447. PubMed ID: 31513841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
    Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
    Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-Specific Genome Engineering in Human Pluripotent Stem Cells.
    Merkert S; Martin U
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of an Induced Pluripotent Stem Cell Line with the Constitutive EGFP Reporter.
    Butterfield KT; McGrath PS; Han CM; Kogut I; Bilousova G
    Methods Mol Biol; 2020; 2155():11-21. PubMed ID: 32474864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective.
    Patmanathan SN; Gnanasegaran N; Lim MN; Husaini R; Fakiruddin KS; Zakaria Z
    Curr Stem Cell Res Ther; 2018; 13(8):632-644. PubMed ID: 29895256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery.
    Ahmad G; Amiji M
    Drug Discov Today; 2018 Mar; 23(3):519-533. PubMed ID: 29326075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR-Cas9 technology: applications and human disease modelling.
    Torres-Ruiz R; Rodriguez-Perales S
    Brief Funct Genomics; 2017 Jan; 16(1):4-12. PubMed ID: 27345434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.